MoonLake Immunotherapeutics reported Q4 2025 and FY 2025 results, ending 2025 with cash, cash equivalents and short-term marketable debt securities of USD 394 million. R&D expenses were USD 56 million in Q4 2025, while G&A expenses were USD 9.2 million. The company said its cash position is expected to fund operating expenses and capital expenditure requirements into H2 2027, and it amended its debt facility with Hercules Capital, including a USD 25 million drawdown and up to USD 400 million in non-dilutive funds remaining available. Alongside the earnings release, MoonLake announced positive topline Phase 2 S-OLARIS data for sonelokimab in axial spondyloarthritis, with 81% of treated patients achieving ASAS40 at Week 12 and more than 80% achieving a clinically important improvement on ASDAS-CRP by Week 12, supported by SPARCC MRI and PET imaging findings. MoonLake also confirmed an Investor Day webcast for February 23, 2026, and reiterated anticipated milestones including 52-week VELA-1/VELA-2 data in hidradenitis suppurativa in Q2 2026 and a planned BLA submission for HS in H2 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602221100PRIMZONEFULLFEED1001165760) on February 22, 2026, and is solely responsible for the information contained therein.
Comments